[go: up one dir, main page]

WO2003023406A3 - Diagnostic method for transmissible spongiform encephalopathies - Google Patents

Diagnostic method for transmissible spongiform encephalopathies Download PDF

Info

Publication number
WO2003023406A3
WO2003023406A3 PCT/EP2002/010063 EP0210063W WO03023406A3 WO 2003023406 A3 WO2003023406 A3 WO 2003023406A3 EP 0210063 W EP0210063 W EP 0210063W WO 03023406 A3 WO03023406 A3 WO 03023406A3
Authority
WO
WIPO (PCT)
Prior art keywords
transmissible spongiform
diagnostic method
spongiform encephalopathies
tse
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/010063
Other languages
French (fr)
Other versions
WO2003023406A9 (en
WO2003023406A2 (en
Inventor
Denis Francois Hochstrasser
Jean-Charles Sanchez
Elisabeth Guillaume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences PLC filed Critical Proteome Sciences PLC
Priority to AU2002331112A priority Critical patent/AU2002331112B2/en
Priority to JP2003527426A priority patent/JP4312049B2/en
Priority to CA002459500A priority patent/CA2459500A1/en
Priority to EP02767478A priority patent/EP1423703A2/en
Publication of WO2003023406A2 publication Critical patent/WO2003023406A2/en
Priority to US10/695,194 priority patent/US20040171026A1/en
Publication of WO2003023406A3 publication Critical patent/WO2003023406A3/en
Publication of WO2003023406A9 publication Critical patent/WO2003023406A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a molecular weight in the range of from 3500 to 30000.
PCT/EP2002/010063 2001-09-05 2002-09-03 Diagnostic method for transmissible spongiform encephalopathies Ceased WO2003023406A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002331112A AU2002331112B2 (en) 2001-09-05 2002-09-03 Diagnostic method for transmissible spongiform encephalopathies
JP2003527426A JP4312049B2 (en) 2001-09-05 2002-09-03 Test method for use in the diagnosis of infectious spongiform encephalopathy
CA002459500A CA2459500A1 (en) 2001-09-05 2002-09-03 Diagnostic method for transmissible spongiform encephalopathies
EP02767478A EP1423703A2 (en) 2001-09-05 2002-09-03 Diagnostic method for transmissible spongiform encephalopathies
US10/695,194 US20040171026A1 (en) 2001-09-05 2003-10-28 Diagnostic method for transmissible spongiform encephalopathies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0121459A GB2379737A (en) 2001-09-05 2001-09-05 Diagnostic method for spongiform encephalopathy disease
GB0121459.2 2001-09-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/695,194 Continuation-In-Part US20040171026A1 (en) 2001-09-05 2003-10-28 Diagnostic method for transmissible spongiform encephalopathies

Publications (3)

Publication Number Publication Date
WO2003023406A2 WO2003023406A2 (en) 2003-03-20
WO2003023406A3 true WO2003023406A3 (en) 2003-11-27
WO2003023406A9 WO2003023406A9 (en) 2004-02-26

Family

ID=9921541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010063 Ceased WO2003023406A2 (en) 2001-09-05 2002-09-03 Diagnostic method for transmissible spongiform encephalopathies

Country Status (6)

Country Link
EP (1) EP1423703A2 (en)
JP (1) JP4312049B2 (en)
AU (1) AU2002331112B2 (en)
CA (1) CA2459500A1 (en)
GB (1) GB2379737A (en)
WO (1) WO2003023406A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274368B2 (en) * 2002-10-30 2008-11-20 Proteome Sciences Plc. Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
RU2299674C2 (en) * 2005-06-21 2007-05-27 Государственное учреждение Научный центр медицинской экологии Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук Method for predicting toxic encephalopathy cases caused by chemical compounds complex
CN114324557B (en) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 Zeta-globin detection method based on MALDI-TOF MS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026293A1 (en) * 1996-12-12 1998-06-18 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
WO2000078344A1 (en) * 1999-06-23 2000-12-28 Caprion Pharmaceuticals, Inc. Prion protein peptides and uses thereof
WO2001025791A2 (en) * 1999-10-07 2001-04-12 Ciphergen Biosystems, Inc. Prostate cancer marker proteins
US6225047B1 (en) * 1997-06-20 2001-05-01 Ciphergen Biosystems, Inc. Use of retentate chromatography to generate difference maps

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19918141A1 (en) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Diagnosing transmissible spongiform encephalopathy, particularly before appearance of clinical symptoms, by detecting specific markers in blood cells
DE19923811C1 (en) * 1999-05-20 2000-12-07 Robert Koch Inst Procedure for the diagnosis of TSE-induced changes in tissues using infrared spectroscopy
GB2360089A (en) * 2000-03-10 2001-09-12 Univ Geneve Diagnostic assay for transmisible spongiform encephalopathies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026293A1 (en) * 1996-12-12 1998-06-18 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
US6225047B1 (en) * 1997-06-20 2001-05-01 Ciphergen Biosystems, Inc. Use of retentate chromatography to generate difference maps
WO2000078344A1 (en) * 1999-06-23 2000-12-28 Caprion Pharmaceuticals, Inc. Prion protein peptides and uses thereof
WO2001025791A2 (en) * 1999-10-07 2001-04-12 Ciphergen Biosystems, Inc. Prostate cancer marker proteins

Also Published As

Publication number Publication date
WO2003023406A9 (en) 2004-02-26
EP1423703A2 (en) 2004-06-02
GB0121459D0 (en) 2001-10-24
JP4312049B2 (en) 2009-08-12
JP2005502882A (en) 2005-01-27
WO2003023406A2 (en) 2003-03-20
CA2459500A1 (en) 2003-03-20
AU2002331112B2 (en) 2006-12-21
GB2379737A (en) 2003-03-19

Similar Documents

Publication Publication Date Title
CA2382531A1 (en) Device for verifying the accuracy of a spectral analyzer
MY139241A (en) Noninvasive blood pressure monitoring system
WO2002064031A3 (en) Multidimensional eye tracking and position measurement system
WO2002043613A3 (en) Method and apparatus for monitoring eye tremor
CA2246876A1 (en) Apparatus for preventing operation of a vehicle or a machine
WO2003015691A3 (en) RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
CA2205359A1 (en) Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-beta peptide (x->=41) and tau
AU1564095A (en) Procedure for verifying the accuracy of non-invasive blood glucose measurement instruments
WO2003048735A3 (en) Processes for the measurement of the potency of glatiramer acetate
EP1974748A3 (en) Antibodies for the diagnosis of diseases associated with fibrosis
BR0206604A (en) Lancet device that has capillary action
NZ332214A (en) Infrared spectroscopic (IR) determination of the characteristics of biological material like blood or other body fluids and determining a change in cellular function
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO1999012471A3 (en) Breath test analyser
WO2001094941A3 (en) Diagnostic methods for pompe disease and other glycogen storage diseases
WO2002081513A3 (en) Disease-associated protein
CA2356442A1 (en) Nmr spectroscopic in vitro assay using hyperpolarization
WO2001061305A3 (en) Immunoassays detecting or making use of at least two rubber latexallergens
WO2007006031A3 (en) Method for the preparation of prrs virus and proteins of and diagnostic test kits for detecting them
CA2364686A1 (en) Prion test
WO2003023406A3 (en) Diagnostic method for transmissible spongiform encephalopathies
WO2002089656A3 (en) Diagnosis of acute myocardial infarction
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
WO2003084384A3 (en) Diagnosis of flavivirus infection
Ødegard et al. Fatigue properties of an A 356(AlSi 7 Mg) aluminum alloy for automotive applications: Fatigue life prediction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10695194

Country of ref document: US

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30

WWE Wipo information: entry into national phase

Ref document number: 2002767478

Country of ref document: EP

Ref document number: 2002331112

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003527426

Country of ref document: JP

Ref document number: 2459500

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002767478

Country of ref document: EP